Overall market sentiment has been high on Beam Therapeutics Inc (BEAM) stock lately. BEAM receives a Bullish rating from InvestorsObserver Stock Sentiment Indicator.
Beam Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on BEAM!
When making investment decisions, sentiment gives a good overview of what stocks investors currently favor. Sentiment incorporates short-term technical analysis into its score and does not encompass any fundamental analysis such as profitability of the company. This means that earnings updates and other news can greatly impact overall sentiment.
Sentiment is how investors, or the market, feels about a stock. There are lots of ways to measure sentiment. At the core, sentiment is pretty easy to understand. If a stock is going up, investors must be bullish, while if it is going down, sentiment is bearish.
InvestorsObserver’s Sentiment Indicator looks at price trends over the past week and also considers changes in volume. Increasing volume can mean a trend is getting stronger, while decreasing volume can mean a trend is nearing a conclusion.
For stocks that have options, our system also considers the balance between calls, which are often bets that the price will go up, and puts, which are frequently bets that the price will fall.
What's Happening With BEAM Stock Today?
Beam Therapeutics Inc (BEAM) stock is trading at $29.82 as of 10:58 AM on Friday, Nov 24, an increase of $0.35, or 1.19% from the previous closing price of $29.47. The stock has traded between $29.40 and $30.47 so far today. Volume today is light. So far 304,396 shares have traded compared to average volume of 1,703,402 shares.
To see InvestorsObserver's Sentiment Score for Beam Therapeutics Inc click here.
More About Beam Therapeutics Inc
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing.
Click Here to get the full Stock Report for Beam Therapeutics Inc stock.
Share this article:
Stay In The Know
Subscribe to our daily morning update newsletter and never miss out on the need-to-know market news, movements, and more.
Thank you for signing up! You're all set to receive the Morning Update newsletter
